학술논문

Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians
Document Type
article
Source
Journal of Eating Disorders. 12(1)
Subject
Health Sciences
Psychology
Anorexia
Brain Disorders
Clinical Trials and Supportive Activities
Eating Disorders
Patient Safety
Clinical Research
Psilocybin
Anorexia nervosa
Clinical trial
Adverse effects
Nutrition and Dietetics
Health sciences
Language
Abstract
BackgroundClinical trials using psilocybin therapy to treat anorexia nervosa (AN) are currently underway. The safety and tolerability of psilocybin is of utmost importance in individuals with AN who may present unique medical vulnerabilities. The purpose of this review is to describe how the common physiologic adverse effects of psilocybin may impact medical complications experienced by individuals with AN in clinical trials of psilocybin therapy.Main bodyThe physiologic underpinnings of common adverse effects following psilocybin administration are described, including tachycardia, hypertension, electrocardiogram changes, nausea, headache, and lightheadedness. These anticipated physiologic changes are described in relation to the common medical correlates seen in individuals with AN. Risk mitigation strategies for each adverse effect are proposed.ConclusionEarly evidence suggests that psilocybin therapy is well-tolerated in individuals with AN. Understanding the unique medical complications of AN, and how they may be impacted by common physiologic adverse effects of psilocybin administration, leads to tailored risk mitigation strategies to enhance safety and tolerability of this novel intervention.